Praxis Precision Medicines Inc.: BTIG Sees 113% Upside Potential and Names the Stock a Top Pick for 2026

Praxis Precision Medicines Inc. (PRAX) is a biotechnology company that specializes in developing therapies for central nervous system (CNS) diseases characterized by an imbalance between neural excitation and inhibition. Unlike broad-based approaches, the company adopts a precision medicine pathway. It leverages genetic insights to target the biological causes of complex brain disorders such as epilepsy and movement disorders. Using proprietary platforms like Cerebrum and Solidus, Praxis identifies specific molecular targets—such as sodium channels—to...